Guidelines for Antibiotic Use During Breastfeeding

Preferred Safe Antibiotics

Beta‑lactams

• Amoxicillin/clavulanic acid is recommended for lactating mothers and is compatible with continued nursing; the recommendation is based on moderate‑quality evidence from the 2025 North American Hidradenitis Suppurativa Guidelines. 1
• Cephalosporins are considered safe, with no documented fetal harm and only minimal transfer into breast milk; this conclusion is supported by moderate‑quality data from the 2020 European Respiratory Journal. 2

Macrolides

• Azithromycin is suggested as safe for use during breastfeeding; the guidance comes from the 2025 North American Hidradenitis Suppurativa Guidelines (moderate evidence). 1

Fluoroquinolones (use with infant monitoring)

• Ciprofloxacin produces very low breast‑milk concentrations (peak ≈ 3.8 mg/L at 2 h, falling to ≈ 0.02 mg/L at 24 h) and an estimated infant exposure of only ≈ 0.57 mg/kg/day; this is derived from the 2025 Global Consensus Statement on IBD Management (moderate‑quality data). 3
• Infants exposed to ciprofloxacin via breast milk experience very few side effects, according to the same IBD consensus (moderate evidence). 3
• When fluoroquinolones are used, infants should be monitored for gastrointestinal effects such as diarrhea and oral/perianal candidiasis; recommendation based on the 2025 IBD consensus (moderate evidence). 3

Other Compatible Antibiotics

• Rifampin may be used in lactating women with the same approach applied to the general population; this is endorsed by the 2025 North American Hidradenitis Suppurativa Guidelines (moderate evidence). 1
• Trimethoprim‑sulfamethoxazole is compatible with breastfeeding in healthy term infants, but should be avoided in premature, jaundiced, or G6PD‑deficient infants; guidance comes from the 2020 European Respiratory Journal (moderate evidence). 2

Antibiotics Requiring Caution

Metronidazole

• Infant exposure to metronidazole can reach ~10 % of a therapeutic infant dose, the highest among commonly used antibiotics; data from the 2025 Global Consensus Statement on IBD Management (moderate evidence). 3
• Routine use of metronidazole during breastfeeding is generally discouraged because of this relatively high exposure (moderate evidence). 3
• If a short course (e.g., ≤1 week) is unavoidable, infants should be closely monitored for diarrhea and candidiasis; recommendation based on the same IBD consensus (moderate evidence). 3
• Peak milk concentrations occur 2–4 h after a 2 g dose and decline over the subsequent 12–24 h, informing timing of infant observation (moderate evidence). 3
• Some guidelines consider metronidazole acceptable with careful monitoring, as stated in the 2025 North American Hidradenitis Suppurativa Guidelines (moderate evidence). 1

Clindamycin

• Clindamycin should be used with caution because it may increase the risk of gastrointestinal side effects in the infant; this caution is highlighted in the 2025 North American Hidradenitis Suppurativa Guidelines (moderate evidence). 1

Tetracyclines (Doxycycline)

• Doxycycline use should be limited to a maximum of 3 weeks without repeat courses; recommendation from the 2025 North American Hidradenitis Suppurative Guidelines (moderate evidence). 1
• Short‑duration doxycycline therapy (3–4 weeks) is compatible with breastfeeding, but prolonged use is discouraged due to theoretical concerns about tooth discoloration and bone growth inhibition; guidance from the 2020 European Respiratory Journal (moderate evidence). 2

Infant Monitoring Recommendations

• Watch for gastrointestinal flora disruption (diarrhea, oral or perianal candidiasis) in infants exposed to any antibiotic, as advised by the 2025 Global Consensus Statement on IBD Management (moderate evidence). 3
• Monitor for drowsiness or poor feeding when the mother is taking fluoroquinolones, recommendation from the 2025 Global Consensus Statement on IBD Management (moderate evidence). 4

Timing Considerations for Milk Concentrations

• Fluoroquinolone milk concentrations are lowest 12–24 h after maternal ingestion, supporting the timing of infant observation; derived from the 2025 IBD consensus (moderate evidence). 3
• Metronidazole peaks in breast milk at 2–4 h post‑dose and declines substantially by 12–24 h, informing optimal monitoring windows (moderate evidence). 3

Clinical Practice Principles

• Do not unnecessarily discontinue breastfeeding when a safe antibiotic is available; this principle is endorsed by the American Academy of Pediatrics (Pediatrics, 2005) (moderate evidence). 5
• The benefits of continued breastfeeding generally outweigh the minimal theoretical risks from antibiotic exposure, as stated by the American Academy of Pediatrics (Pediatrics, 2005) (moderate evidence). 5

Evidence Quality Summary

• The 2025 Global Consensus Statement on IBD Management and the 2025 North American Hidradenitis Suppurativa Guidelines provide the most current evidence, with the majority of recommendations based on moderate‑quality data and expert consensus. [3][6][1][7]

Antibiotic Use in Breastfeeding Mothers: Evidence‑Based Recommendations

Preferred Antibiotics with Evidence

• Vancomycin is considered low‑risk for nursing infants, with no reported adverse effects when used by breastfeeding mothers 8.

Antibiotics Requiring Caution

• Metronidazole results in infant exposure of approximately 10.6 % of the therapeutic infant dose—the highest among commonly used antibiotics, indicating relatively high milk transfer; therefore routine use during lactation is discouraged [@1].
• If metronidazole is essential for a short course (≤ 1 week), infants should be closely monitored for diarrhea and oral/perianal candidiasis; peak milk concentrations occur 2–4 hours after maternal dosing and decline over the next 12–24 hours, allowing timing of feeds to minimize exposure [@1].
• Ciprofloxacin yields very low breast‑milk concentrations (peak ≈ 3.79 mg/L at 2 h, falling to 0.02 mg/L at 24 h) and an estimated infant exposure of only 0.57 mg/kg/day, making it acceptable when indicated, but infants should be observed for gastrointestinal effects such as diarrhea and candidiasis [@1].
• Clindamycin should be used with caution in lactating women because of a potential increased risk of gastrointestinal side effects in infants; it is reserved for patients with penicillin allergy who are at high risk for anaphylaxis in specific clinical scenarios [@2, @3, @4].

Infant Monitoring Recommendations (Supported by Evidence)

• When any antibiotic is administered to a breastfeeding mother, clinicians should monitor the infant for signs of gastrointestinal flora disruption (e.g., diarrhea, oral or perianal candidiasis) [@1].

Breastfeeding While Using Oral Metronidazole

Guideline Recommendations

• The 2025 North American clinical practice guidelines for hidradenitis suppurativa (American Academy of Dermatology) conditionally recommend oral metronidazole for breastfeeding patients when systemic antibiotics are needed, based on moderate‑quality evidence. 9
• The 2020 European Respiratory Society guidelines state that metronidazole may be used during lactation if no safer alternative exists, classifying it as “possibly safe.” This is a conditional recommendation with moderate evidence. 10

Pharmacokinetic Considerations

• Peak metronidazole concentrations in breast milk occur 2–4 hours after the maternal dose and decline markedly over the next 12–24 hours, suggesting that timing of feeds can reduce infant exposure. (moderate evidence) 10

Clinical Management

When Metronidazole Is Essential

• Continue breastfeeding while closely monitoring the infant for gastrointestinal disturbances (diarrhea, oral/perianal candidiasis). This approach is endorsed by the American Academy of Dermatology with moderate evidence. 9
• Limit the course to ≤ 1 week whenever feasible to minimize infant exposure (expert consensus).

Preferred Safer Alternatives (moderate evidence)

All alternative recommendations are from the American Academy of Dermatology guidelines. 9

Antibiotics Requiring Caution (moderate evidence)

• Clindamycin – Use cautiously because of an increased risk of infant gastrointestinal side effects. 9
• Doxycycline – Restrict to ≤ 3 weeks and avoid repeat courses. 9

Feeding Timing to Reduce Exposure (moderate evidence)

• If a single 2 g dose of metronidazole is administered, withholding breastfeeding for 12–24 hours after the dose may be considered, although this is not mandatory. 10

Infant Monitoring Protocol

• Observe the nursing infant for diarrhea or loose stools as the primary adverse effect reported. (moderate evidence) 10
• Monitor for oral thrush and perianal candidiasis (clinical vigilance recommended, though not directly cited).

Safety Considerations & Evidence Summary

• Recent guideline bodies (2025) prioritize continuation of breastfeeding with monitoring, noting that documented infant harm is rare despite theoretical concerns. (conditional recommendation, moderate quality) 9
• The FDA label emphasizes a theoretical tumorigenicity risk from animal studies, but no human infant adverse outcomes have been demonstrated. (theoretical risk, not cited)

Practical Pitfalls to Avoid

• Do not discontinue breastfeeding unnecessarily when metronidazole is clinically indicated and no safer alternatives are available. (strong recommendation) 11
• Do not use metronidazole as first‑line therapy when equally effective, safer antibiotics exist. (moderate evidence) 9
• Avoid prolonged or repeated courses without reassessment of necessity and consideration of alternatives. (expert consensus)

Overall Benefit‑Risk Assessment

• The benefits of continued breastfeeding generally outweigh the minimal documented risks from metronidazole exposure via breast milk, provided that appropriate infant monitoring is maintained. (moderate evidence) 11